Role of clarithromycin in the management of multiple infection
DOI:
https://doi.org/10.18203/2320-6012.ijrms20244169Keywords:
Macrolides, Azithromycin, Antibiotic resistance, Clarithromycin, Respiratory tract infections, COVID-19Abstract
Clarithromycin, a second-generation semisynthetic macrolide antibiotic, is known for its broad-spectrum antibacterial activity, favorable pharmacokinetic profile, and stability at gastric pH, along with significant anti-inflammatory and immunomodulatory effects. It demonstrates superior efficacy and fewer side effects compared to other macrolides, making it a potent therapeutic option for various bacterial infections. Clarithromycin is approved for use in combination therapy to eradicate Helicobacter pylori and for treating mild to moderately severe respiratory infections such as acute exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP) including infections from Chlamydia, Mycoplasma spp., acute streptococcal pharyngitis, and skin and soft tissue infections. Apart from its usual listed uses, clarithromycin is used in multiple other infections, including upper respiratory tract infections (URTIs) like pharyngitis in penicillin-allergic patients, chronic pharyngitis related to gastroesophageal reflux disease (GERD), sore throat, acute laryngitis, and chronic rhinosinusitis. It is also effective for lower respiratory tract infections (LRTIs) related to chronic obstructive pulmonary disease (COPD), Mycobacterium avium complex (MAC) infections, bronchiectasis, and various other conditions including COVID-19, systemic lupus erythematosus (SLE), bronchiolitis obliterans syndrome post-lung transplant, and H. influenzae infections. During the COVID-19 pandemic, concerns about antimicrobial resistance from the overuse of antibiotics, including azithromycin, highlighted clarithromycin as a preferable alternative due to its superior pharmacodynamics and lower resistance risk. While clarithromycin has a favorable safety profile, it is associated with potential adverse effects such as cardiovascular risks and gastrointestinal disturbances. Its role as a reserve antibiotic highlights its importance in managing resistant infections and in situations where first-line treatments are ineffective or contraindicated.
Metrics
References
Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides—a systematic review of the underlying mechanisms. Front Immunol. 2018;9:302.
Naik P, Prabhat D, Shrivastava R, Nair A, Khandke DA. Clarithromycin: overview and its current clinical utility in the treatment of respiratory tract infections. Int J Res Med Sci. 2024;12(2):1.
Jednačak T, Mikulandra I, Novak P. Advanced Methods for Studying Structure and Interactions of Macrolide Antibiotics. Int J Mol Sci. 2020;21(20):7799.
Zuckerman J. Macrolides and ketolides: Azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am. 2004;18:621-49.
Tanwir S, Sabah A, Khatoon A, Afridi FI. Increased antimicrobial resistance against azithromycin during COVID: role of irrational utilization. J Pak Med Assoc. 2024;74(2):258-71.
Lee JW. Clarithromycin. Helicobacter pylori: Springer. 2024;485-95.
Karakike E, Scicluna BP, Roumpoutsou M, Mitrou I, Karampela N, Karageorgos A, et al. Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial. Crit Care. 2022;26(1):183.
Altunaiji SM, Kukuruzovic RH, Curtis NC, Massie J. Cochrane Review: Antibiotics for whooping cough (pertussis). Evidence-Based Child Health. 2012;7(3):893-956.
Coutinho G, Duerden M, Sessa A, Caretta‐Barradas S, Altiner A. Worldwide comparison of treatment guidelines for sore throat. Int J Clin Pract. 2021;75(5):e13879.
Clarithromycin approved uses- USFDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050662s044s050,50698s026s030,050775s015s019lbl.pdf. Accessed on 12 October 2024.
Clarithromycin approved drug-CDSCO. 2022. Available at: https://cdscoonline.gov.in/CDSCO/ Drugs. Accessed on 12 October 2024.
Aumpan N, Mahachai V, Vilaichone Rk. Management of Helicobacter pylori infection. JGH Open. 2023;7(1):3-15.
Gopalkrishnan R, Walia K, Ohri V. Treatment Guidelines for Antimicrobial Use in Common Syndromes 2nd edition: Indian Council of Medical Research. 2019. Available at: https://main.icmr.nic.in/ sites/default/files/guidelines/Treatment_Guidelines_2019_Final.pdf. Accessed on 12 October 2024.
Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86-102.
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52.
Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009;119(11):1541-51.
Agwuh K. Skin and Soft Tissue Infection Guideline, including Diabetic Foot Ulcer Infection. 2022. Available at: https://www.dbth.nhs.uk/wp-content/ uploads/2022/. Accessed on 12 October 2024.
Antibiotic prescribing in primary care: Therapeutic Guidelines summary table 2023. Australian Commission on Safety and Quality in Health. 2023. Available at: https://www.safetyandquality.gov.au/ sites/default/files/2023-05/gpsummary_v15.pdf. Accessed on 12 October 2024.
Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, Doulou S, Kakavoulis N, Tsiakos K, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Resp Med. 2024;12(4):294-304.
Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, and the Canadian Community-Acquired Pneumonia Working G. Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An Evidence-Based Update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31(2):383-421.
Kim NN, Marikar D. Antibiotic prescribing for upper respiratory tract infections: NICE guidelines. Arch Dis Child Educ Pract Ed. 2020;105(2):104-6.
Goto H. Multicenter surveillance of adult atypical pneumonia in Japan: its clinical features, and efficacy and safety of clarithromycin. J Infect Chemother. 2011;17(1):97-104.
Kalra MG, Higgins KE, Perez ED. Common questions about streptococcal pharyngitis. Am Fam Physician. 2016;94(1):24-31.
Onyekwere CA, Odiagah JN, Igetei R, Emanuel AOD, Ekere F, Smith S. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. World J Gastroenterol. 2014;20(13):3615.
Worrall G. Acute sore throat. Can Fam Physician. 2011;57(7):791-4.
Hoban DJ, Nauta J. Clinical And Bacteriological Impact Of Clarithromycin In Streptococcal Pharyngitis: Findings From A Meta-Analysis Of Clinical Trials. Drug Des Devel Ther. 2019;13:3551-8.
Reveiz L, Cardona AF. Antibiotics for acute laryngitis in adults. Cochrane Database Syst Rev. 2015;2015(5):CD004783.
Rechtweg JS, Moinuddin R, Houser SM, Mamikoglu B, Corey JP. Quality of life in treatment of acute rhinosinusitis with clarithromycin and amoxicillin/clavulanate. Laryngoscope. 2004;114(5):806-10.
Bhargava SK, Peethambaran K. Pharmacotherapy of Chronic Rhinosinusitis with a Focus on Clarithromycin: An Expert Opinion. J Assoc Physicians India. 2018;66(10):74-9.
Luo Q, Chen F, Liu W, Li Z, Xu R, Fan Y, et al. Evaluation of long-term clarithromycin treatment in adult Chinese Patients with chronic rhinosinusitis without nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2011;73(4):206-11.
Lin CF, Wang MC, Merton AT, Ho NH, Wu PS, Hsu AT, et al. Add-on effect of clarithromycin to oral steroids as post- operative therapy for chronic rhinosinusitis with nasal polyps: a randomised controlled trial. Rhinology. 2020;58(6):550-8.
Perot B, Baban M. The Role of the Macrolide in Preventing Recurrence of the Nasal Polyposis after Fess. Pak J Med Health Sci. 2021;14(3):1291-5.
Varvyanskaya A, Lopatin A. Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery. Int Forum Allergy Rhinol. 2014;4(7):533-41.
Chen H, Zhou B, Huang Q, Li C, Wu Y, Huang Z, et al. Efficacy and Safety of Long-Term Low-Dose Clarithromycin in Patients With Refractory Chronic Sinusitis After Endoscopic Sinus Surgery: A Prospective Clinical Trial. Ear Nose Throat J. 2024;103(1):NP31-9.
El-Shinnawi M, Loizou P, Barbaccia C, Varma A. Management of Persistent Postnasal Drip Without Sinus Affection. Am J Interdisciplin Res Innov. 2024;3:1-6.
Ashy N, Alharbi L, Alkhamisi R, Alradadi R, Eljaaly K. Efficacy of erythromycin compared to clarithromycin and azithromycin in adults or adolescents with community-acquired pneumonia: A Systematic Review and meta-analysis of randomized controlled trials. J Infect Chemother. 2022;28(8):1148-52.
Al-Salloum J, Gillani SW, Mahmood RK, Gulam SM. Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review. J Int Med Res. 2021;49(10):3000605211049943.
Miravitlles M, Llor C, Naberan K, Cots JM, Molina J. Effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in primary care. Clin Drug Investig. 2004;24:63-72.
Martinot JB, Carr WD, Cullen S, Heredia Budo JL, Bauer K, MacLeod C, et al. A comparative study of clarithromycin modified release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv Ther. 2001;18(1):1-11.
Neu HC, Chick TW. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest. 1993;104(5):1393-9.
Yamazaki Y, Ushiki A, Kubo K, Tanabe Y, Koyama S. Antimicrobial and anti-inflammatory effects of clarithromycin on Mycobacterium avium complex replication in cultured human bronchial epithelial cells. J Infect Chemother. 2012;18(5):683-8.
Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994;121(12):905-11.
Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996;335(6):384-91.
Gassiep I, Chaudhuri A. Is there a role for antimicrobial stewardship in bronchiectasis? Chron Respir Dis. 2015;12(3):274-5.
Fouka E, Lamprianidou E, Arvanitidis K, Filidou E, Kolios G, Miltiades P, et al. Low-Dose Clarithromycin Therapy Modulates Th17 Response In Non-Cystic Fibrosis Bronchiectasis Patients. Lung. 2014;192(6):849-55.
Yalçin E, Kiper N, Ozçelik U, Doğru D, Firat P, Sahin A, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther. 2006;31(1):49-55.
Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520-31.
Metzler K, Drlica K, Blondeau JM. Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2013;68(3):631-5.
Snow TAC, Longobardo A, Brealey D, Down J, Satta G, Singer M, et al. Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19. J Infect Chemother. 2022;28(7):948-54.
Ohe M, Kataoka H, Mukai M. A case of lupus nephritis treated with clarithromycin, tacrolimus, and glucocorticoids. Kaohsiung J Med Sci. 2016;32(9):484-5.
Benden C, Boehler A. Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation. 2009;87(10):1538-40.
Knower MT, Labella-Walker K, McFadden PM, Kantrow SP, Valentine VG. Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients. South Med J. 2000;93(11):1087-92.
Iino Y, Yoshida N, Kato T, Kakizaki K, Miyazawa T, Kakuta H. Clinical effects of clarithromycin on persistent inflammation following Haemophilus influenzae-positive acute otitis media. Acta Otolaryngol. 2015;135(3):217-25.
Lee C-W, Tai Y-L, Huang L-M, Chi H, Huang F-Y, Chiu N-C, et al. Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric influenza patients. J Microbiol Immunol Infect. 2021;54(5):876-84.
Hung IF, To KK, Chan JF, Cheng VC, Liu KS, Tam A, et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A (H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest. 2017;151(5):1069-80.
Higashi F, Kubo H, Yasuda H, Nukiwa T, Yamaya M. Additional treatment with clarithromycin reduces fever duration in patients with influenza. Resp Investig. 2014;52(5):302-9.
Yamaya M, Shinya K, Hatachi Y, Kubo H, Asada M, Yasuda H, et al. Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther. 2010;333(1):81-90.
Domon H, Isono T, Hiyoshi T, Tamura H, Sasagawa K, Maekawa T, et al. Clarithromycin Inhibits Pneumolysin Production via Downregulation of ply Gene Transcription despite Autolysis Activation. Microbiol Spectr. 2021;9(2):e0031821.
Kyriazopoulou E, Sinapidis D, Halvatzis S, Velissaris D, Alexiou N, Kosmas V, et al. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study. Int J Antimicrob Agents. 2020;55(1):105836.
Lee JH, Kim HJ, Kim YH. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis. J Korean Med Sci. 2017;32(1):77-84.
Zhao P, Yao R, Yang J, Wen W, Yao Y, Du X. Efficacy and safety of clarithromycin for patients with sepsis or septic shock: a systematic review and meta-analysis. Emerg Crit Care Med. 2024;4(2).
Evans J, Hanoodi M, Wittler M. Amoxicillin clavulanate. 2023 Aug 16. StatPearls. Treasure Island (FL): StatPearls Publishing. 2023.
Hoban DJ, Nauta J. Clarithromycin Amoxicillin alone or with Clavulanate in Acute Maxillary Sinusitis: A Meta-analysis of Clinical Trials. Open Infect Dis J. 2021;13.
Slay RM, Hewitt JA, Crumrine M. Determination of the Postexposure Prophylactic Benefit of Oral Azithromycin and Clarithromycin Against Inhalation Anthrax in Cynomolgus Macaques. Clin Infect Dis. 2022;75(3):S411-s6.
Tsiakos K, Tsakiris A, Tsibris G, Voutsinas PM, Panagopoulos P, Kosmidou M, et al. Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial. Infect Dis Ther. 2021;10(4):2333-51.
Júnior VCR, Sabattini AC. Impact of Azithromycin on the Predisposition to Cardiac Arrhythmias in Adult Patients: A Systematic Review. SCT Proceedings in Interdisciplinary Insights and Innovations. 2024;2:329.
Alispahic IA, Eklöf J, Sivapalan P, Jordan AR, Harboe ZB, Biering-Sørensen T, et al. Risk of Mortality and Cardiovascular Events in Patients with Chronic Obstructive Pulmonary Disease Treated with Azithromycin, Roxithromycin, Clarithromycin, and Amoxicillin. J Clin Med. 2024;13(7).
Seetharam R, Iyer RB, Nooraine J, Ramachandran J. Clarithromycin-induced Seizures and Status Epilepticus. Indian J Crit Care Med. 2021;25(8):945-7.
Kuçukbayrak A, Senel E, Kücükbayrak ZS, Gunay E, Simsek E. Vesiculobullous eruption of the right arm after intravenous clarithromycin. Indian J Pharmacol. 2011;43(1):82-3.
Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310(23):2544-53.
Hougaard Christensen MM, Bruun Haastrup M, Øhlenschlæger T, Esbech P, Arnspang Pedersen S, Bach Dunvald AC, et al. Interaction potential between clarithromycin and individual statins—A systematic review. Basic Clin Pharmacol Toxicol. 2020;126(4):307-17.
Ruan XC, Tan PY, Tan Y. Clarithromycin and glipizide drug-drug interaction leading to refractory hypoglycemia. Cureus. 2019;11(6).
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246-55.
Villa Zapata L, Hansten PD, Horn JR, Boyce RD, Gephart S, Subbian V, et al. Evidence of Clinically Meaningful Drug–Drug Interaction With Concomitant Use of Colchicine and Clarithromycin. Drug Safety. 2020;43(7):661-8.
Vieweg WVR, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk A. Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports. Therap Adv Infect Dis. 2013;1(4):121-38.
Downloads
Published
How to Cite
Issue
Section
